Prior authorization is frustrating to clinicians, but a new survey from the American Medical Association shows it also frustrates patients to the point of abandoning care. The survey showed many more insights regarding PA impact on care.

The newly cleared devices are all designed to detect signs of PAD and/or PVD early enough that limb amputation is not required. 

Reviewing a patient's medical history can help care teams select the optimal post-TAVR oral anticoagulation strategy.

A veteran cardiologist in Boston has filed a new lawsuit that claims she is earning a much lower salary than a less experienced male colleague. She believes this violates the Massachusetts Equal Pay Act.

The new PREVENT CVD risk calculator could result in more than 16 million heart patients who are no longer eligible for preventive therapy. These significant changes “carry the potential for both benefit and harm," researchers wrote in JAMA.

There is still a lack of lack of standardized treatment protocols for pulmonary embolism. This is mainly due to limited data and a lack of reliable risk assessments, one specialist explained.

The Elixir Medical DynamX sirolimus-eluting coronary bioadaptor is designed to improve coronary luminal diameter, help restore hemodynamic modulation and reduce plaque progression in patients with de novo coronary artery lesions.

Compounded semaglutide injectable products are at the heart of these concerns. While the FDA says compounded drugs “can serve an important medical need for patients,” the agency does not approve these new formulations, increasing the risk of complications. 

Nearly 130 healthcare groups are urging Congress to pass legislation that would provide relief to U.S. physicians struggling to keep up with wave after wave of payment reductions.

While JenaValve is known for its Trilogy Heart Valve System, a device designed specifically to treat aortic regurgitation, Endotronix specializes in developing heart failure technologies. The news comes after Edwards sold its critical care business for $4.2 billion in June, saying it would double down on its structural heart portfolio.